

Keyword Index for Volume 89

- α -catenin 557
 α -fetoprotein 1086
 α -MSH 2004
 α -tocopheryl succinate 1822
1100delC 1966
¹⁹F magnetic resonance spectroscopy 754, 1796
5-aminolaevulinic acid 405, 730
5-fluorouracil 239, 455, 754, 803, 816, 944, 992, 1796, 2213
72 kDa type IV collagenase 1270
7271T>G mutation 1513
- A3 adenosine receptor 1552
abdomino-perineal resection 2019
ablation 2227
abnormal nucleation 1802
accelerated proliferation 2184
acceptability 1400
ACIS 886
actin 860
acute hypoxia 350
adenocarcinoma 834, 2078
adenoviral cytolysis 577
adenovirus 385, 1162, 2140
adjuvant therapy 1042, 1433, 1837, 2062
adrenomedullin 1927
adriamycin 1423
adult height 81
adult leg length 81
adult trunk length 81
advanced cancer 23, 77
advanced gastric cancer 2207
advanced gastrointestinal cancer 2051
advanced melanoma 1901
advanced NSCLC 2190
Africa 65
aggregation state 937
AIDS 94, 505
AKT 185, 391, 2110
ALA efflux 173
ALA uptake 173
albumin 1028
alcohol 1667
allelic loss 2289
alpha-interferon 50
alveolar soft-part sarcoma 243
anal carcinoma 2057
anatomic site 1202
androgen deprivation 971
androgen-independent cell 1566
androgen receptor 552
aneusomy 128
angiogenesis 215, 1375, 1395, 1927
angiopoietins 891
annexin V 1327
anthracyclines 36, 666
anthropometry 519
- antiangiogenesis 243, 262, 907, 1395
antibody–cytokine fusion protein 1130
antibody response 291
antigens 199
antioxidants 1255
antiproliferative 907
antisense oligonucleotides 1352
antitumour effect 1102
AP-2 transcription factor 899
APC 1298
Apo2L/TRAIL 206
apoptosis 178, 192, 206, 363, 564, 727, 763, 915, 944, 1035, 1091, 1108, 1327, 1345, 1358, 1366, 1590, 1620, 1757, 1776, 1802, 1817, 1822, 1896, 1950, 1979, 2155, 2244, 2277
apoptosis resistance 1714
apoptosome 2147
arginine 907
arginine deiminase 907
arginine deprivation 573
arthropometry 81
aspirin 1705
association 1524
astrocytoma grade II 128
ataxia telangiectasia 1091
ATM gene screening 1513
ATP-TCA 2299
autologous transplantation 29
axilla 1310
- β -catenin 152, 557, 1298
 β 1-integrin 374, 2122
 β 3-integrin 2122
B cell lymphoma 2155
B16-F10.9 melanoma 314
bacteriochlorophyll 2333
Barrett's oesophagus 1508
Bax 1590
BCG immunotherapy 2312
BCL-2 55, 391
Bcl-x_L 1352
BCRP/MXR/ABCP/ABCG2 1971
Belarus and Ukrainian registries 2098
benign prostatic hypertrophy 106
best supportive care 2219
betel chewing 681, 1202
bilateral breast cancer 1513
biomarkers 8, 1940
biopsy 8
birth weight 1664
bispecific antibody 1987
bisphosphonates 178
biweekly schedule 239
bladder cancer 298, 1096, 1290, 2264, 2271, 2312
blindness 2038
- blood flow 2333
blood pressure 1243
body mass index 513, 519, 1667
body size 852
bone markers 2031
bone marrow 539
bone metastases 178, 625, 660
BRAF 1958
brain 1743
brain tumour 577
breast 277, 524
breast cancer 15, 77, 81, 113, 135, 178, 185, 192, 284, 305, 492, 508, 533, 539, 648, 660, 666, 840, 847, 977, 983, 1035, 1185, 1255, 1502, 1513, 1627, 1645, 1664, 1686, 1693, 1750, 1789, 1920, 1934, 2062, 2227, 2289
breast cancer genetic risk counselling 653, 1650
breast cancer in young women 1661
breast cancer risk 1672
breast density 852
breast tumour 271, 487, 1310
bronchoscopy 1885
brotallicin 1559
brush border 1995
bryostatin-1 1152, 1418
- C26 murine colon carcinoma 754
Ca19-9 1413
CA9 877
cachexia 1116
calcitriol 968
caloric restriction 1375, 2254
camptothecin 1757
cancer awareness 2165
cancer cachexia 2254
cancer care 821
cancer diagnostics 1067
cancer incidence 1709
cancer of oral cavity and oropharynx 1667
cancer pain 2027
cancer patients 1055
cancer relative survival 74
cancer risk 308
cancer vaccine 1079
canine 1530
capecitabine 615, 1627, 1843
carbonic anhydrase IX 2, 1067, 1290
carboplatin 803, 1901
carcinoid 455, 1383
carcinoma 524, 1610
case–control studies 23, 88, 831, 840, 1225, 1228, 2087
caseload 15, 492
- caspase-9 1366
caspases 2147
cathepsin 1574
Caveolin 1909
CB1954 944
CD151 158
CD1a 533
CD26/DPPIV 1366
CD4 1736
CD40 ligation 1162
CD8 1736
CD95 363, 1950
CDDP 2207
cDNA array 564
cell cycle 120, 564, 763, 1091, 1920, 2305
cell death 1574, 1590
cell lines 2289
cell surface molecules 1463
cell-cycle 1776
cell-death assay 1789
c-erbB-2 513, 959
cervical cancer 101, 834, 1248
cervical cancer screening model 1830
cervical cytology 88
cervical intraepithelial neoplasia 109
cervix 65
cervix neoplasms 2078
CF101 1552
checkpoint 1966
CHEK2 1966
chemically induced hepatocellular carcinoma 730
chemically induced squamous cell carcinoma 2320
chemoprevention 412, 1705
chemoradiation 1433
chemosensitivity test 1896
chemotherapy 206, 477, 634, 727, 840, 966, 968, 1035, 1192, 1428, 1439, 1517, 1605, 1627, 1849, 2038, 2045, 2057, 2299
child 2038
childhood cancer 1215, 1228
Chinese 1686
Chlamydia trachomatis 831
choroid plexus 1743
choroid plexus tumour 1743
chromosome 17 720, 1530
chronotherapy 1870
cigarette smoking 1202
CIN 831
cinical benefit 2207
cisplatin 585, 617, 795, 1192, 1633, 1860, 2045
cisplatinum 1849
citrulline 573, 907
classic Kaposi's sarcoma 1657
clear cell sarcoma 1072

- clinical nurse specialist 15
 clinical trial 8, 1152
 clonotypic PCR 1876
 clorgyline 1979
 cluster analysis 305
 CMF 1837
 CML 1162, 1855
 c-Myc 1479
 Coexisting CIN 886
 cognition 971
 cohort analysis 1260
 cohort study 465, 505, 1221, 1238, 1664, 1709
 colitic cancer 1232
 collaboration 15
 collagen crosslinks 1722
 Colo 205 1995
 colon 1358
 colon cancer 158, 363, 374, 1352, 1439, 1552, 2277
 colorectal adenoma 152
 colorectal cancer 23, 146, 465, 477, 612, 707, 992, 1155, 1232, 1638, 1870, 1876, 2051, 2299
 colorectal cancer patients 1400
 colposcopy 109
 combination chemotherapy 795, 992, 1789
 combretastatin A-4 1334
 comet assay 2264, 2271
 communication 2069
 communication skills training 1445
 comparative genomic hybridisation (CGH) 720, 864, 1530
 compliance 497
 computed tomography scan 482
 computer-aided detection 1645
 concomitant drugs 1013
 concurrent chemoradiation 795
 conflict of interest 1405
 confocal fluorescence microscopy 1581
 consensus method 821
 continuous infusional 5-fluorouracil 2051
 contralateral breast cancer 513
 controlled-release morphine 2027
 controlled-release oxycodone 2027
 core biopsy 1310
 cost – benefit analysis 109
 cost-effectiveness 634
 cost-minimisation 1002
 COX-2 1358
 CpG island methylation 338
 CpG-oligonucleotides 2312
 CPT-11 2178
 C-reactive protein 612, 1028
 CT antigen 291
 CTL 1079
 culture 539
 cumulative prognostic score 1028
 cyclin D 1995
 cyclin D1 1920
- cyclooxygenase-2 1102
CYP1B1 1524
CYP3A4 1855
 cytochrome *P450* 1855
 cytokeratin 539
 cytokines 524, 1463
 cytological grading 36
 cytology 109
 cytosine deaminase 1796
 cytoskeleton 860
 cytostatic 1995
 cytotoxic drugs 2133
 cytotoxicity 199, 1166
- δ -aminolevulinic acid 173
 D122 Lewis lung carcinoma 314
 DAXX 1950
 DCE-MRI 1889
 DCIS 277, 1920
 DcR2 206
 death receptors 1714
 DEB theory 2254
 decision-making 2219
 deficiency 573
 degradative enzymes 1123
 deletion 1729
 dendritic cells (DCs) 533, 1162, 1172, 1463, 1736
 depletion 1633
 deprivation 612, 1650
 desmoplastic small round-cell tumour 1159
 dextran derivative 215
 diagnosis 1645, 1885, 2098
 diagnostic classification 1599
 diet 1255, 1672
 differentiation 140, 146
 dihydropyrimidine dehydrogenase 816, 1486
 dissociation 1817
 D-loop 697
 DNA damage 333, 1366, 1479, 2271
 DNA microarrays 314
 DNA minor groove binder 1559
 DNA mismatch repair 1559
 DNA repair 333
 DNA strand breaks 2277
 docetaxel 630, 795, 968
 dog 1530
 domiciliary 2190
 dominant negative 1276
 dose individualisation 787
 dose intensity 2062
 dosimetry 840
 doxifluridine 1627
 doxorubicin 357, 1545, 2140
 drug distribution 1581
 drug resistance 185, 1581, 1971
 drug sensitivity 1559
 DSB 593
 Du145 593
 dysplasia 1232
- E2F 120
 early breast cancer 1837
 early diagnosis 1048
 early life risk 81
- EBV gene expression 113
 E-cadherin 557
 ECF 1433
 ECOG 1022
 economic evaluation 634
 effectiveness 88
 EGFR 681, 1285, 2327
 EGTR 1776
 elderly 992, 1428, 1439, 1827
 ELISPOT assay 1172
 endogenous granzyme B 135
 endometrial cancer 546, 697, 891, 2023
 endometrial hyperplasia 891
 endometrial neoplasms 1697
 endothelial growth factors 426
 energy expenditure 2254
 EORTC QLQ-C30 497
 EPA 1116
 gastritis 1743
 ependymoma 1743
 epidemiology 94, 101, 1205, 1221, 1243, 1661, 1705
 epidermal growth factor receptor 1266
 epidermal/mucosal reactions 1102
 epidermoid carcinoma A431 cells 215
 epirubicin 617, 1192
 epithelium 707
 Epstein–Barr virus (EBV) 344, 1200
ERBB2 promoter 899
 ET-743 2305
 ethnic origin 641
 ethnicity 70, 508
 EWS/ATF1 1072
ex vivo 1789
 excimer dye laser 730
 expression 1729
 extracapsular dissection 1610
 extragonadal germ cell tumours 29
- facial nerve palsy 1610
 FADD 1950
 faecal occult blood 23
 familial prostate cancer 691
 fas ligand 1345
 fat 1672, 1686
 Fc γ RI 2234
 febrile neutropenia 43
 fermented wheat germ extract 465
 FGFR3IIIc 1276
 FGFR3IIIS 1276
 Fhit 320
 fibroblasts 1473
 fish 1686
 flavones 1255
 flavonoids 1255
 flow cytometry 1971
 fluoropyrimidine 615, 1843
 fluoropyrimidine-based chemotherapy 1486
 fluorouracil 585, 615, 1155
- focal adhesion kinase 140
 focused ultrasound surgery 2227
 FOLFOX4 455
 folic acid 239
 follicular lymphoma 36
 follow-up 482
 Foscan 398
FOXO1A 327
 fruits 1209
 functional classes 1940
 fund raising 2165
- γ -irradiation 727
 G2/M checkpoint 1479
 gadopentetate dimeglumine 1889
 gallbladder cancer 1736
 gastric cancer 676, 1314, 1428, 1433, 2051
 gastritis 1314
 gastrointestinal neoplasms 426
 gastrointestinal stromal tumours 460
 G-CSF 2234
gef gene 192
 gefitinib 1827
 gelatinase A 1270
 gemcitabine 239, 1180, 1192, 1413, 1865, 2190, 2299
 gene amplification 552
 gene expression 314, 564, 1508, 1914
 gene expression profiling 1599
 gene therapy 192, 2155
 genetic testing 1400
 Germany 1205
 germ-cell tumours 787, 1849, 2202
 gestational trophoblastic disease 2197
 Gleason score 106
 Gleevec 1855
 glioblastoma 1896, 2122
 glioma 248, 727, 922, 1172, 1375, 1896
 Glivec 634, 1403, 1855
 GLUT-1 870, 1290
 glutathione 1108
 GM-CSF 1162
 grade 1096
 graded-field gel electrophoresis 593
 growth factor 178
 growth hormone 524, 1108
 growth pattern 852, 1920
 GSK3 β 1298
 GSTM1 1502
 GSTT1 1502
- HAART 457
 haematological 1389
 haemoglobin 977
 haemolymphopoietic neoplasms 94
 haemolysis 1334
 haplotype 1524
 HCT-15 1995

- head and neck cancer 585
 head and neck squamous cell carcinoma 864
 health economics 1405
 heat shock cognate protein 70 1079
 HeLa 593
Helicobacter pylori 1314
 hepatectomy 1493
 hepatic artery chemoembolisation 1423
 hepatic neoplasms 1423, 1493
 hepatocellular carcinoma 291, 730, 1086, 1614, 1865
 hepatocyte culture 1493
 hepatocyte injury 1423
 Her-2 681
 hereditary 1524
 hereditary nonpolyposis colorectal cancer 1400
 HER-2/neu 666, 959, 983, 1305, 2110, 2234
 HER-2/neu peptides 1055
 HIF 877
 high-dose carboplatin 787
 high-dose chemotherapy 29, 787, 1159
 high-grade cervical dysplasia 1062
 high grade intraepithelial lesions 101
 high-intensity focused ultrasound 2227
 histology 109
 HIV 457, 502, 505
 HLA-A26 1055
 HLA-A3 1055
 HLA-B46 1079
 HMGA2 2104
 hnRNP K protein 1493
 Hodgkin's disease 482
 hormone replacement therapy 277, 1697
 hormone-resistant prostate cancer 552
 hormones 1147
 hPif1 713
 HPV 831, 1248
 HPV genotypes 886
 HSP27 1950
 HSV-TK 1086
 HT-29 1995
 hTERT 922, 1473
 human catalase 2140
 human glioma cell line 1802
 human mammary epithelial cells 1479
 human monoclonal antibody 1545
 human papillomavirus 101, 1830
 human papilloma virus load 109
 human papillomavirus-16 672
 Hurthle cell carcinoma 258
 HUVECs 357
 hyperbilirubinaemia 1403
 hypermethylation 1473
 Hypersensitivity reaction 477
 hyperthermia 405, 2333
 hypomagnesaemia 1633
 hypopharynx 1940
 hypoxia 271, 870, 1290, 2133
 hypoxia-inducible factor 2
 hypoxia-inducible-factor 1 α 1042
 I157T 1966
 IAP 2147
 ICBP90 120
 IGF-1 1375
 IL-12 1552
 IL-2 1876
 IL-6 338
 imatinib 460, 1403, 1855
 immortalization 2293
 immune privilege 1345
 immunochemical test 23
 immunocytochemistry 899
 immunocytokine 1130
 immunohistochemistry 140, 320, 546, 1042, 1729, 1736, 1927, 2249
 immunoliposomes 1545
 immunostaining 2104
 immunotherapy 385, 1130, 1147, 1162, 1172, 2213, 2234
 imprint cytology of biopsied sample 1885
 incidence 70, 834, 1205
 induction chemotherapy 2184
 infants 1605
 infertility 1849
 infrared-A-radiation 405
In situ hybridisation 128, 891
 insulin 1697
 insulin-like growth factor binding protein-1 (IGFBP-1) 1697
 insulin-like growth factor binding protein-3 (IGFBP-3) 1697
 insulin-like growth factor-I (IGF-I) 1697
 interferon alpha 2213
 interferon alpha-2b 243
 interleukin-2 50, 1620, 2213
 interstitial fluid pressure 1334
 intestinal metaplasia 1314
 intralesional therapy 1620
 intramuscular administration 1228
 invasion 1123, 1270, 2122
 invasive lymphocytes 113
in vitro 2133
 ionising radiation 1102, 1479, 1709, 1802
 'Iressa' 585
 Irinotecan 617, 630, 992, 997, 1008, 1439, 1860, 1870
 Israeli Jews 1657
 IVS10-6T>G mutation 1513
 JAK/STAT pathway 338
 Japanese population 691
 jaundice 1403
 JCOG 2178
 JNK 1950
 KAI1/CD82 158
 Kaplan-Meier 232
 Kaposi's sarcoma 502
 keratinocytes 1473
 ketogenic diet 1375
 Ki-67 index 128
 kidney cancer 1418
 kidney tumour 1285
KIT gene 460
 knockout mice 1776
 KSHV 1657
 KSHV/HHV-8 502
 lactate dehydrogenase 877
 language of consultation 641
 laryngeal brushing 1048
 larynx 1048
 laser scanning cytometry 8
L-deprenyl 1979
 leadership 15
 leanness 1667
 leukaemia 1228, 1638
 lichen sclerosis 2249
 life-course 852
 LIG-1 1285
 linkage 505
 lipiodol 1423, 1614
 liposarcoma 1409
 liposomal doxorubicin 1180
 liver metastases 284
LKB1/STK11 308
 LNCaP 593
 local tumour control 2019
 loss of heterozygosity 333, 2289
 low-dose methotrexate 2197
 low-risk 43
 lung cancers 320, 702, 795, 959, 1013, 1022, 1705
 LVT 930
 lymphangiogenesis 426
 lymphatic system 426
 lymph node metastasis 1042, 1750, 2116
 lymphoma 1530, 2087
 lysosomes 1574
 magnesium 1633
 malignancies 1389
 malignant effusion 1876
 malignant fibrous histiocytoma 720
 malignant transformation 2293
 mammary cancer 385
 mammographic parenchymal patterns 852
 mammography 1645
 MAPK 185
 marine natural compounds 763
 matrix metalloproteinase-2 2122
 matrix metalloproteinase-7 2116
 matrix metalloproteinase-9 2116
 MBD2 1934
 MCF-7 593
MC1R 1961
 MDX-H210 2234
 MeCP2 1934
 mediastinal primary 29
 megakaryocytic differentiation 1320
 mEH 702
 melanocortin 2004
 melanocytes 1072
 melanoma 573, 1123, 1517, 2004
 melanoma-follow-up 1457
 melanoma-prognosis 1457
 men 1243
MET 327
 meta-analysis 55, 101, 1672
 meta-iodobenzylguanidine 1383
 metabolic control 1375
 metabolic status 2333
 metabolism 573
 metastasis 314, 557, 1270, 1909, 2004
 metastatic bone disease 2031
 metastatic colorectal cancer 1486
 metastatic gastric cancer 997
 methyl-CpG-binding protein 1934
 MIBG 1383
 microarray 1599, 1757, 1914
 microenvironment 2
 micrometastasis 676
 micronuclei 727
 microsatellite instability 707
 midkine 1086
 migrants 508
 migration 1123
 minichromosome maintenance protein-2 1048
 missing data 781
 MTF 1072
 mitochondrial DNA 697
 mitochondrial microsatellite instability 697
 mitogen-activated protein kinase (MAPK) 1783
 mitomycin C 2051, 2299
 mitoxantrone 1971
 MMP 1817
 MMP-2 1123
 molecular epidemiology 702
 molecular mechanisms 585
 monoamine oxidase inhibitors (MAOIs) 1979
 MonoHER 357, 2140
 morbidity 648
 morphology 1693
 mortality 77
 mouse 1796
 mouth 2244
 MRP-1/CD9 158
 MTC 2093
 m-THPC 398
 MTT 357, 2140
 MUC1 1130
 multidisciplinary team 15
 multivariate analysis 1166

- mutations 308, 1729, 1958, 1971, 2249
 myeloprotection 1552
 myogenesis 327

 n-3 fatty acids 1686
 n-3 polyunsaturated fatty acids 1102
 n-6 fatty acids 1686
 N-telopeptide 2031
 Na⁺/H⁺ antiporter 1395
 nasopharyngeal carcinoma (NPC) 344
 natural killer cells (NKs) 1130, 1552, 1736
 natural regression 1062
 NE tumours 1776
 neoadjuvant chemotherapy 1185
 neonatal cardiac myocytes 2140
 neoplastic disease 1243, 1260, 1822
 neuroblastoma 412, 470, 860, 1605
 neuroendocrine tumour 455
 neuropsychology 2038
 neutropenia 1837, 2062
 neutrophil adhesion 357
 neutrophils 1345
 NF-kappaB 2004
 NF-κB 391, 1108, 1116, 1358
 NICE 966
 nitroreductase 944
 NO 907
 node-positive breast cancer 268
 noncytotoxic 1166
 non-Hodgkin's lymphoma 713, 1958, 2087
 nonimmune cells 135
 nonseminomatous histology 29
 non-small-cell lung cancer 55, 246, 457, 877, 1008, 1028, 1192, 1789
 normal cells 1147
 normal ovary 1298
 normoxia 2133
 Norway 1238
 Nottingham prognostic index 1185
 NSAIDs 1358
 NSCLC 1827, 2184
 Ntx 2031
 nucleophosmin/B23 1320
 nude mice 1383

 obesity 519
 occupational exposures 1215
 octreotide 258
 oesophageal adenocarcinoma 1508, 1729
 oesophageal cancer 140, 630, 1202, 1209, 2299
 oesophageal squamous cell carcinoma 1042
 oesophagus 2045
 oestrogen and progesterone receptor status 1661
 oestrogen receptor 113, 1934

 OK-432 1876
 oligodendroglioma 2327
 O⁶-methylguanine-DNA-methyltransferase 1517
 oncogenes 1305, 1958
 oncogenesis 1395
 oncologist 1022
 oncology 1405
 optic pathway glioma 2038
 oral antibiotics 43
 oral cancer 681
 oral chemotherapy 808, 1627
 oral mucosa 2244
 oral squamous cell carcinoma 557, 1722
 organ transplantation 1221
 orotate phosphoribosyl transferase 1486
 osteosarcoma 206
 OT 930
 outcome and process assessment (health care) 15
 outpatient 43
 ovarian cancer 672, 966, 1002, 1152, 1180, 1298, 1843, 2293
 ovarian neoplasm 1002
 ovarian surface epithelium 2293
 overexpression 1574
 oxaliplatin 1155, 1439, 1870
 oxygenation 2333
 oxygen consumption 937
 oxygen tension 350
 oxytocin receptor 930

 p16 1802
 p185 959
 p21^{WAF1/CIP1}-induction 1566
 p21^{WAF1/CIP1}-deficit cell 1566
 p21^{Waf1/Cip1} 1757
 p31 EBV DNA 113
 p38MAPK 564
 p53 320, 707, 727, 1314, 1729, 2249
 p53 tumour suppressor gene 672
 paediatric Hodgkin's lymphoma 1200
 palladium-bacteriopheophorbide 2320
 palliative care 2069
 palliative chemotherapy 1860, 2219
 Pancreatic adenocarcinoma 239, 1714
 pancreatic cancer 391, 1413, 1860, 1987, 2104, 2110
 pancreatic ductal adenocarcinoma 338
 pancreatic neoplasms 519
 papillomavirus 94
 Pap smears 88
 parotid gland 1610
 patient-doctor communication 2202
 patient participation 2069
 patient preferences 1450
 patient selection 1860

 PAX3 327
 PAX7 327
 PCR 1750
 pegylated liposomal doxorubicin hydrochloride 1002
 performance status 1022, 1028
 period analysis 1260
 period survival 74
 peripheral benzodiazepine receptor 564
 peripheral lung cancer 1885
 peritoneal cytology 2023
 PET 8
 PET imaging 1327
 Peutz-Jeghers syndrome 308
 P-glycoprotein 1581
 pH 2
 pharmaceutical targets 1940
 pharmacodynamics, hamster tumour model 2320
 pharmacokinetics 398, 816, 1776, 1822, 1855
 phase I study 617, 1166, 1901
 phase I/II study 2051
 phase II 997, 1418, 1428
 phase II study 1008
 phase III trial 1192
 phenylacetate 412
 phenytoin 615
 pheochromocytoma 1383
 phosphatidylserine 1327
 phospholipase A₂ (PLA₂) 1783
 phospholipase C (PLC) 1783
 photodynamic diagnosis 730
 photodynamic therapy 173, 398, 405, 730, 937, 1590, 2320, 2333
 photosensitiser 937, 2320
 pH regulation 1395
 phthalocyanine Pc 4 1590
 physical activity 847
 physician patient relations 2069
 pimonidazole 1290
 plasminogen activation and metastasis 374
 platinum compound 477
 pO₂ fluctuations 350
 point mutations 687
 polyethylene glycol 937, 1545
 polylysine conjugate 937
 polymorphisms 702, 1096, 1502, 1517
 polyomavirus 385
 polypharmacotherapy 1013
 polyunsaturated fatty acids 1686
 pooled analysis 1638
 poor PS patients 1827
 population pharmacokinetics 787
 positron emission tomography 262
 potassium 1633
 PPAR_γ 1409
 preclinical models 2327
 preconception exposure 1709
 predictive assay 2277
 predictive factors 977
 predictive test 2264

 predictors 1062, 1248
 preterm birth 1664
 prevention 2165
 primary care 1650
 primary chemotherapy 666, 977
 primary language 641
 procarbazine 248
 prognosis 128, 140, 271, 298, 460, 470, 660, 681, 720, 1022, 1166, 1260, 1266, 1450, 1502, 2045
 prognostic classification 1599
 prognostic factors 546, 959, 2116
 prognostic indices 1909
 prognostic variables 284
 progression-free and overall survival 465
 prolactin 524
 proliferation 128, 1035, 1493, 1817
 proliferation index 2093
 promoter 1086
 prospective cohort study 847
 prospective studies 1705
 prostate cancer 106, 625, 968, 971, 1055, 1238, 1524, 1966
 prostate tumours 687
 proteasome expression 1116, 1783
 protein catabolism 1116
 protein kinase C 1152, 1418
 proteolysis-inducing factor 1116, 1783
 proteome 305
 psychological impact 653
 pyridinoline 1722

 quality of life 50, 497, 641, 648, 971, 1843, 2202
 quantitative real-time RT-PCR 271, 1750
 question prompt list 2069

 radiation 593, 1215, 2305
 radiation enhancement 1987
 radiation protection 1979
 radioimmunoassay 1927
 radioiodine 258, 1638
 radioligand 930
 radiosensitisation 577, 1352, 2264, 2271, 2305
 radiosensitizer 746
 radiotherapy 65, 298, 840, 2023, 2038, 2057, 2271
 Raman spectroscopy 106
 RARRES3 146
 RAS 185, 1958
 rat sarcoma 405
 razoxane 262
 RCAS1 546
 RCC 1285
 reactive oxygen species 1314
 recombinant bacteria 1796
 rectal cancer 870
 recurrence 277, 1920
 registries 1205, 1260

- relapse 482
renal cell carcinoma 50, 1266, 1909, 2147, 2213
repeated events 781
residual disease 1185
resistance 206, 1147
response 277
retinoblastoma protein 120, 298
retinoblastoma tumour suppressor gene 135
retinoid 808
retinoyl glucuronide 412
reverse transcription-polymerase chain reaction 676
rhabdomyosarcoma 327
rhenium-188-HEDP 625
RhG-CSF 1008
RIG 1 146
rinse-fluid cytology of forceps and brush 1885
risk factors 519, 831, 2078
rituximab 1389
RNASEL gene 691
RNF11 1538
rosiglitazone 1409
RT112 593
RT-PCR 1457, 2104
rural health services 821
- S-1 816, 2207
salted meat 1209
sarcoma 720
scFv 1130
Scotland 505
screening 23, 77, 1645
screening interval 88
seasonality 1200
second cancer 840
second-line treatment 2213
second primary malignancies 1638
senescence 1473
sentinel lymph node 676, 1750
sentinel lymph node biopsy 648
seroprevalence 1248
serrated adenoma 152
serrated polyp 152
service delivery 653, 1650
sex steroids 385
sexual functioning 2202
side effects 1633
signal transducers and activators of transcription (STAT) 344
simvastatin 1855
skeletal-related events 2031
skin neoplasms 1205
SM-11355 1614
Small cell lung cancer 55, 2178
smoking 831, 1667, 2087
Smurf2 1538
- socioeconomic status 1693
SOCS 524
SOCS-1 338
soft-tissue melanoma metastases 1620
soluble protein 1276
somatostatin receptor 258
South Asians 508
southern blot assay 676
SPARC molecular markers 1508
splice variant 1276
sponsorship 1405
squamous cell carcinoma 101, 834, 1048, 2078, 2244
squamous cell carcinoma of the vulva 2249
squamous dysplasia 1048
stage 1028, 1693
stage 4s 470
stage III 1457
stamps 2165
statistical methods 232
stem cells 1776
steroid receptors 268
stewed meat 1209
streptozocin 455
stroma 707
stroma-supported immunocytoometric assay 763
superficial oesophageal cancer 2116
supportive care 1013
suppressor genes 687
surgery 460, 487
surveillance colonoscopy 1232
survival 55, 65, 487, 508, 533, 612, 660, 834, 864, 959, 1260, 1610, 1693, 1837, 1896, 2023, 2045, 2093
survival analysis 232, 271, 781
survivin 1743, 2244
susceptibility 1502
synergy 746, 944
systemic inflammatory response 612
systematic review 55, 959
- T47D 593
tamoxifen 268, 277
tankyrase 713
targeting 1545
tazarotenic acid 808
T-cell precursor frequencies 1055
T-cell receptor (TCR) 1876
Tcf/Lef 1298
TCL1 1091
telomerase 713, 922
telomere 1091
temporofin 398
temozolomide 248, 922, 1901
- temporal heterogeneity in pO_2 350
testicular cancer 2202
testicular germ cell tumours (TGCTs) 2133
Tet system 2155
TGCT cytokine 915
TGF β signalling 1538
therapeutic efficiency 625
therapy 1147, 1358, 2227
thoracic radiation therapy 803
thyroid cancer 1638, 2098
TIG3 146
TIMP 1817
tissue 1147
tissue samples 1722
TK 1776
TM4SF 158
TNF 1096
TNF- α 1123
toll-like receptor 2312
Tookad[®] 2320
topoisomerase II 1366
topoisomerase II α 120, 666
topotecan 1002, 1789
toxicity 2057
TPA 1320
TRAIL 363, 2155
TRAIL receptors 363
trans-arterial chemoembolisation 1614
transforming growth factor- β 1345
transitional cell carcinoma 1305
trastuzumab 983
treatment 65, 470, 492
treatment choice 2219
treatment preference 2219
TRF1 713
TRF2 713
tropomyosin 860
truth disclosure 2069
tumorigenesis 1817
tumour antigens 1067, 1130
tumour biology 1508
tumour blood flow 1334
tumour doubling time 2184, 2254
tumour epitopes 1079
tumour growth rate 2254
tumour immunity 199, 1463
tumour marker 1927
tumour models 1581
tumour necrosis factor alpha 1987
tumour perfusion 262
tumour response 977
tumour suppressor gene 146
tumour thickness 2019
tumour vessel 1334
TUNEL 1327
- two-dimensional electrophoresis 305
tyrosinase 1457
tyrosine kinase 1783
tyrosine kinase inhibitor 246, 1889
tyrosine kinase phosphorylation 983
- ubiquitination 1538
Uganda 502
ulcerative colitis 1232
ultrasound 1310
understanding of disease status 641
‘unknown’ genes 1940
unresectable 1605
upper gastrointestinal cancer 497
urokinase plasminogen activator receptor 374
uveal melanoma 1914, 1961
- vaccination 199
validation 781
vascular endothelial growth factor 215, 268
vascular invasion 1909
vascular permeability 1889
VDEPT 944
vegetables 1209
VEGF 1889
VEGF-B 891
vesicular monoamine transporter 1383
vinorelbine and paclitaxel 1566
virtual Northern 1940
visual acuity 2038
vitamin D 746, 968
vitamin E analogues 1822
vitamin K 1228
VMAT 1383
- waiting times 492, 2184
whitehall 1243
WHO classification 36
wide local excision 2019
WISP-1 314
Wnt-signalling 1298
Wnt signal transduction 152
women 2087
workload 15, 487
written information 1450
- xenograft human tumour 1796
xenografts 577, 2289, 2327
xeroderma pigmentosum 333
young women 88
- ZD 1839, 246, 585
ZD6474 1889
zemplar 746